|Awarded On||August 20, 2014|
|Title||Reversing Vaccination-Induced Impairment of Anti-CTLA-4- Based Cancer Therapy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Willem Overwijk|
Anti-CTLA-4 antibody (ipilimumab, Yervoy®) is an effective new therapy for patients with metastatic melanoma that strengthens the immune system’s attack on cancer cells. Experimental vaccines against melanoma, including gp100 vaccine, are designed to do the same. Thus it was a surprise when combination of anti-CTLA-4 with gp100 vaccine did not work better, and in fact slightly worse, than anti-CTLA-4 alone. It is important to understand why vaccination did not improve anti-CTLA-4 therapy, because it was expected to be a very effective ways to improve anti-CTLA-4 therapy for the benefit of more patients with melanoma and possible other cancers. Because of these perplexing results, it is now u...